Several therapeutic approaches targeting T cell activation (i.e., Janus kinase inhibitors) and proinflammatory cytokines (i.e., antibodies against IL17, IFNγ, and TNFα) have been developed for the treatment of autoimmune disorders. Here, IL17A is linked to autoimmune disease.